28Jul
04Jun
Zylö Therapeutics Closes $5.225 Million Series B Financing
Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing. The Series B round was led by a consortium of seasoned investors, spearheaded by James Cordes, who recently joined the Zylö board of directors. Other key participants were: (i) VentureSouth (which led the Series A round) which invested more than $1.3 million in the Series B round; (ii) the New York Angels, an angel group that has played...
23Dec
Startup: Zylö Therapeutics — Small company, big idea
Scott Pancoast believes he can put Greenville on the map with his company’s product, and he’s ready to take it to the world. Zylö Therapeutics is a technology startup that uses a silica powder, called Z-pods — very similar in consistency to talcum powder — to be the vehicle of transport for everything from pain relievers to pesticides. The Z-pods have far-reaching medical applications, as they’ve shown promise in promoting hair growth, treating acne, relieving pain, helping with erectile dysfunction...
09Dec
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Read more >>
09Dec
Zylö Therapeutics receives $300K investment from SC Launch
SC Launch Inc., South Carolina Research Authority (SCRA’s) investment affiliate, announced Dec. 7 it has invested $300,000 in Zylö Therapeutics Inc., a medical research business in Greenville. Read more >>
07Dec
SC Launch, Inc. Announces Third Investment in Zylö Therapeutics
South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch, Inc. has made its third investment into Zylö Therapeutics, Inc. This $300,000 investment will help the company continue providing therapeutic topical solutions. Read more >>
19Nov
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Read more >>
11Nov
Zylö’s Erectile Dysfunction Product Concept Wins Best Abstract Award
A novel nitric-oxide-releasing product concept developed by Zylö Therapeutics was awarded Best Abstract - Basic Science at the annual scientific meeting of the North American Sexual Medicine Society of North America (SMSNA), held October 21-24 in Scottsdale. Read more>>
08Oct
Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Read more >>
04Sep